Ashtead Technology Holdings PLC

• DC Diranko Capital Quarterly Letter Q3 2026 ↗ Diranko Capital sold Lifecore Biomedical after Webster Equity Partners’ bid offered limited value for opaque contingent payments, validating its emphasis on buying below replacement cost. It also built Ashtead Technology around mission-critical offshore equipment, monopoly-like pricing power and industry consolidation before an indicative takeover approach emerged. Q3 2026 AT $561MLFCR $244M
• Royce Investment Partners Royce International Premier Fund Manager Commentary ↗ Royce International Premier Fund retained CTS Eventim, Business Engineering, Cochlear, OBIC Business Consultants, and Hemnet despite share-price weakness, arguing that durable market positions and depressed valuations outweigh cyclical and AI-related concerns. It exited Intertek following EQT's acquisition and attributes relative weakness to stock selection and limited exposure to the AI infrastructure supply chain. first half of 2026 4828 $514MAT $561MCEVMF $6.7B +7

All coverage of AT →